Table 1.

Clinicopathological characteristics of patients with α-internexin immunohistochemical detection

Demographic and Clinical Characteristics		N	%
GEP-NENs (n = 286)
Sex	Male	173	60.5
	Female	113	39.5
Age (years) at diagnosis	≤50	134	46.9
	> 50	152	53.1
	Median (range)	53 (16–85)
Functional status	Nonfunctional	234	81.8
	Functional	52	18.2
	Insulinoma	42	14.7
	Vasoactive intestinal polypeptidoma	7	2.4
	Carcinoid syndrome	1	0.3
	Somatostatinoma	1	0.3
	Gastrinoma	1	0.3
Tumor location	Gastrointestinal tract	162	56.6
	Rectum	60	21.0
	Stomach	43	15.0
	Duodenum	21	7.3
	Esophagus	18	6.3
	Jejunum/ileum	9	3.1
	Appendix	6	2.1
	Colon	5	1.7
	Pancreas	93	32.5
	Other	31	10.8
	Metastasis of unknown primary	25	8.7
	Biliary tract	5	1.7
	Greater omentum	1	0.3
Tumor gradea	G1	120	43.2
	G2	57	20.5
	G3	101	36.3
Tumor typea	NET	180	64.7
	NET G1	120	43.2
	NET G2	57	20.5
	NET G3	3	1.1
	NEC	91	32.7
	MANEC	7	2.5
Tumor stage	I	79	27.6
	II	61	21.3
	III	45	15.7
	IV	101	35.3
GI-NENs (n = 162)
Tumor gradeb	G1	60	38.5
	G2	21	13.5
	G3	75	48.1
Tumor typeb	NET	81	51.9
	NET G1	60	38.5
	NET G2	21	13.5
	NEC	70	44.9
	MANEC	5	3.2
Tumor stage	I	48	29.6
	II	26	16.0
	III	37	22.8
	IV	51	31.5
pNENs (n = 93)
Tumor gradec	G1	54	59.3
	G2	27	29.7
	G3	10	11.0
Tumor typec	NET	84	92.3
	NET G1	54	59.3
	NET G2	27	29.7
	NET G3	3	3.3
	NEC	7	7.7
	MANEC	0	0
Tumor stage	I	30	32.3
	II	30	32.3
	III	4	4.3
	IV	29	31.2

^a 278 cases both for tumor grade and tumor type; ^b 156 cases both for tumor grade and tumor type; ^c 91cases both for tumor grade and tumor type

GEP-NEN Gastroenteropancreatic neuroendocrine neoplasm, NET Neuroendocrine tumor, NEC Neuroendocrine carcinoma, MANEC Mixed adenoneuroendocrine carcinoma, GI-NEN Gastrointestinal neuroendocrine neoplasm, pNEN Pancreatic neuroendocrine neoplasm